Janar Sathananthan, Ole De Backer, and Michael Reardon dive into the newest findings on TAVR from the late-breaking ACURATE IDE trial.

Though X (formerly Twitter) was once a place many cardiologists found community and opportunity, many are jumping ship.

An increased risk of cardiovascular disease may be present as early as 30 years before a type 2 diabetes diagnosis is made, ...

The SMART trial raised questions about balloon-expandable valves in small aortic annuli; these new data offer some answers.

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Host Shelley Wood hears some scientific session highlights from AHA President Keith Churchwell.

Randomized trials of platelet function and genetic testing to guide antiplatelet decisions following PCI have produced notoriously mixed results: now, an updated consensus document aims to fill some ...

The study was stopped early to allow all patients with advanced PAH the option for treatment with the activin signaling ...

A multistate model that enables real-time risk recalculations may help improve risk stratification for prediction of ...